Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19 by Machado, Felipe V C et al.








Construct validity of the Post-COVID-19 Functional Status Scale in adult
subjects with COVID-19
Machado, Felipe V C ; Meys, Roy ; Delbressine, Jeannet M ; Vaes, Anouk W ; Goërtz, Yvonne M J ; et
al ; Barco, Stefano
Abstract: BACKGROUND An increasing number of subjects are recovering from COVID-19, raising the
need for tools to adequately assess the course of the disease and its impact on functional status. We
aimed to assess the construct validity of the Post-COVID-19 Functional Status (PCFS) Scale among
adult subjects with confirmed and presumed COVID-19. METHODS Adult subjects with confirmed and
presumed COVID-19, who were members of an online panel and two Facebook groups for subjects with
COVID-19 with persistent symptoms, completed an online survey after the onset of infection-related
symptoms. The number and intensity of symptoms were evaluated with the Utrecht Symptom Diary,
health-related quality of life (HrQoL) with the 5-level EQ-5D questionnaire, impairment in work and ac-
tivities with the Work Productivity and Activity Impairment questionnaire and functional status with the
PCFS Scale. RESULTS 1939 subjects were included in the analyses (85% women, 95% non-hospitalized
during infection) about 3 months after the onset of infection-related symptoms. Subjects classified as
experiencing ’slight’, ’moderate’ and ’severe’ functional limitations presented a gradual increase in the
number/intensity of symptoms, reduction of HrQoL and impairment in work and usual activities. No
differences were found regarding the number and intensity of symptoms, HrQoL and impairment in work
and usual activities between subjects classified as experiencing ’negligible’ and ’no’ functional limitations.
We found weak-to-strong statistical associations between functional status and all domains of HrQoL (r:
0.233-0.661). Notably, the strongest association found was with the ’usual activities’ domain of the 5-
level EQ-5D questionnaire. CONCLUSION We demonstrated the construct validity of the PCFS Scale
in highly-symptomatic adult subjects with confirmed and presumed COVID-19, 3 months after the onset
of symptoms.
DOI: https://doi.org/10.1186/s12955-021-01691-2






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Machado, Felipe V C; Meys, Roy; Delbressine, Jeannet M; Vaes, Anouk W; Goërtz, Yvonne M J; et
al; Barco, Stefano (2021). Construct validity of the Post-COVID-19 Functional Status Scale in adult
subjects with COVID-19. Health and Quality of Life Outcomes, 19:40.
DOI: https://doi.org/10.1186/s12955-021-01691-2
2
Machado et al. Health Qual Life Outcomes           (2021) 19:40  
https://doi.org/10.1186/s12955-021-01691-2
RESEARCH
Construct validity of the Post-COVID-19 
Functional Status Scale in adult subjects 
with COVID-19
Felipe V. C. Machado1,2,3,4* , Roy Meys1,2,3, Jeannet M. Delbressine1, Anouk W. Vaes1, Yvonne M. J. Goërtz1,2,3, 
Maarten van Herck1,2,3,5, Sarah Houben-Wilke1, Gudula J. A. M. Boon6, Stefano Barco7,8, Chris Burtin5, 
Alex van ’t Hul9, Rein Posthuma1,2,3, Frits M. E. Franssen1,2,3, Yvonne Spies10, Herman Vijlbrief10, Fabio Pitta4, 
Spencer A. Rezek11, Daisy J. A. Janssen1,12, Bob Siegerink13,14, Frederikus A. Klok6,7 and Martijn A. Spruit1,2,3,5
Abstract 
Background: An increasing number of subjects are recovering from COVID-19, raising the need for tools to ade-
quately assess the course of the disease and its impact on functional status. We aimed to assess the construct validity 
of the Post-COVID-19 Functional Status (PCFS) Scale among adult subjects with confirmed and presumed COVID-19.
Methods: Adult subjects with confirmed and presumed COVID-19, who were members of an online panel and two 
Facebook groups for subjects with COVID-19 with persistent symptoms, completed an online survey after the onset of 
infection-related symptoms. The number and intensity of symptoms were evaluated with the Utrecht Symptom Diary, 
health-related quality of life (HrQoL) with the 5-level EQ-5D questionnaire, impairment in work and activities with the 
Work Productivity and Activity Impairment questionnaire and functional status with the PCFS Scale.
Results: 1939 subjects were included in the analyses (85% women, 95% non-hospitalized during infection) about 
3 months after the onset of infection-related symptoms. Subjects classified as experiencing ‘slight’, ‘moderate’ and 
‘severe’ functional limitations presented a gradual increase in the number/intensity of symptoms, reduction of HrQoL 
and impairment in work and usual activities. No differences were found regarding the number and intensity of symp-
toms, HrQoL and impairment in work and usual activities between subjects classified as experiencing ‘negligible’ and 
‘no’ functional limitations. We found weak-to-strong statistical associations between functional status and all domains 
of HrQoL (r: 0.233–0.661). Notably, the strongest association found was with the ‘usual activities’ domain of the 5-level 
EQ-5D questionnaire.
Conclusion: We demonstrated the construct validity of the PCFS Scale in highly-symptomatic adult subjects with 
confirmed and presumed COVID-19, 3 months after the onset of symptoms.
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Background
As of January, 12th 2021, more than 88.3 million con-
firmed cases of the corona virus disease 2019 (COVID-
19) causing approximately 1.900.000 deaths were 
reported globally [1]. Nevertheless, the total number of 
subjects with COVID-19 is probably higher due to insuf-
ficient testing capacity and/or difficulties in identifying 
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mild cases [2–4]. Previous severe acute respiratory syn-
drome (SARS) outbreaks showed to affect the survivors’ 
lung function, exercise capacity, health-related quality of 
life (HrQoL), mental health, and lead to increased symp-
toms of fatigue and dyspnea from 6  months to 2  years 
after symptom onset [5–7]. Due to the increasing num-
ber of subjects recovering from the infection of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
the need for tools to measure and monitor the course of 
the disease and its impact on functional status has been 
raised as essential [8].
Klok and colleagues proposed the “Post-COVID-19 
Functional Status (PCFS) Scale” to be used as a patient-
reported outcome measure to evaluate the consequences 
of COVID-19 and their effect on functional status [8]. 
The PCFS Scale can be used both at the time of hospi-
tal discharge, and to monitor functional status post dis-
charge [8]. The scale was designed to cover the entire 
range of functional limitations from: grade 0, “No func-
tional limitations” to grade 4, “Severe functional limita-
tions” and grade 5, “Death”. Notably, the scale was derived 
for measuring functional outcomes after venous throm-
boembolism (VTE), by use of a Delphi method among 
international VTE experts and patient focus groups [9, 
10]. It was found to have good to excellent interobserver 
agreement between self-reported scale assessment and 
a structured interview by a trained physician [10]. Since 
COVID-19 represents an acute cardiopulmonary disease, 
and has been shown to be frequently complicated by 
VTE [11], the scale was assumed to be relevant and use-
ful in the clinical course of COVID-19 too [8]. The scale 
and supporting information such as a manual and various 
translations are freely accessible via https ://osf.io/qgpdv / 
(CC-BY 4.0). To date, however, no study has investigated 
any measurement property of the PCFS Scale in post-
COVID-19 subjects.
The aim of the present study was, therefore, to assess 
the construct validity of the PCFS Scale among adult sub-
jects with confirmed and presumed COVID-19 by testing 
the hypothesis that this simple tool is associated with the 
number and intensity of symptoms, HrQoL and impair-
ment in work and usual activities due to health.
Methods
Study design, setting and participants
This cross-sectional, survey study was conducted in the 
Netherlands and Flanders (Belgium) between June 4th 
and June 11th 2020. Members of two Facebook groups 
for COVID-19 subjects with persistent complaints 
[12, 13] and subjects who registered at a website of the 
Lung Foundation Netherlands (www.coron along plein 
.nl) received a web link with an invitation to fill out 
questionnaires.
Subjects were asked one-off to provide information 
regarding anthropometric/sociodemographic charac-
teristics and medical history (gender, age, height, body 
weight, date of onset of symptoms, hospitalization at the 
time of the infection, type of COVID-19 diagnosis, num-
ber of pre-existing comorbidities, marital and smoking 
status). Subjects were stratified into four groups accord-
ing to the type of COVID-19 diagnosis: (1) hospitalized 
with confirmed COVID-19 (regular ward, no admission 
to intensive care unit (ICU); (2) non-hospitalized with 
confirmed COVID-19 (based on reverse transcription 
polymerase chain reaction (RT-PCR) test and/or com-
puted tomography (CT) scan of the thorax); (3) non-hos-
pitalized with symptom-based diagnosis of COVID-19 
(established by a doctor, no formal COVID-19 testing); 
and (4) non-hospitalized with presumed COVID-19 (no 
formal diagnosis at the time of the presumed infection).
The medical ethics committee of Maastricht Univer-
sity stated that the Medical Research Involving Human 
Subjects Act (WMO) does not apply for this study and 
that an official approval of this study by the committee 
was not required (METC2020-1978). The medical eth-
ics committee of Hasselt University formally judged and 
also approved the study (MEC2020/041). All subjects 
gave digital informed consent at the start of the survey. 
Data from this study on persistent symptoms and care 
dependency have been published before [14–16].
Construct validity
The present study adopted the definition of one of the 
three domains of validity (construct validity) described in 
the COSMIN study—which aimed to clarify and stand-
ardize terminology and definitions of measurement 
properties that are relevant and should be evaluated for 
health-related patient-reported outcomes (HR-PRO) 
[17]. Construct validity is defined as the degree to which 
the scores of a HR-PRO instrument are consistent with 
hypotheses (for instance with regard to relationships to 
scores of other instruments) based on the assumption 
that the HR-PRO instrument validly measures the con-
struct to be measured [17]. For this reason, we opted to 
investigate the construct validity of the PCFS Scale by 
testing whether the PCFS Scale is a simple tool that can 
be used for measuring the impact of symptoms on the 
functional status of subjects. Our hypothesis is that the 
PCFS Scale is related with instruments used to assess the 
number and intensity of symptoms as well as with instru-
ments which assess the impairment in HrQoL and in 
work and usual activities. In order to test this hypothesis, 
we explored the level of impairment in these outcomes 
(see below) after stratifying subjects according to the 
PCFS Scale.
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Measures
To assess the level of impairment in functional status 
subjects were asked to fill in the PCFS Scale [8]. The 
PCFS Scale stratification is composed of five scale grades: 
grade 0 (No functional limitations); grade 1 (Negligible 
functional limitations); grade 2 (Slight functional limi-
tations); grade 3 (Moderate functional limitations) and 
grade 4 (Severe functional limitations). The final scale 
grade 5 ‘death’, which is required to be able to use the 
scale as outcome measure in clinical trials, was left out 
for this self-administered questionnaire. Additionally, 
the following questionnaires were completed: the Utre-
cht Symptom Diary (USD), an adapted Dutch version of 
the Edmonton Symptom Assessment System [18, 19], to 
assess symptom intensity ranging from 0 (no symptom) 
to 10 points (worst possible); the 5-level version of the 
EQ-5D questionnaire (EQ-5D-5L) to assess HrQoL [20]. 
This questionnaire is composed by five domains (mobil-
ity, self-care, usual activities, pain/discomfort and anxi-
ety/depression) and a visual analogue scale (VAS) ranging 
from 0 (the worst imaginable health) to 100 points (the 
best imaginable health). From the scores of each domain, 
an index can be calculated (ranging from −  0.329 to 1) 
with higher scores representing a better HrQoL [21]; and 
the Work Productivity and Activity Impairment (WPAI) 
questionnaire from which four main outcomes can be 
generated and expressed in percentages: (1) percent 
work time missed due to health (absenteeism); (2) per-
cent impairment while working due to health (presentee-
ism); (3) percent overall work impairment due to health; 
(4) percent activity impairment due to health. The recall 
period is 7 days and higher scores represent more impair-
ment in outcomes, the questionnaire has shown to be 
valid and reproducible and has been extensively used in 
different common chronic diseases [22, 23].
Statistical analyses
Continuous variables are presented as mean and stand-
ard deviation or median and interquartile range, as 
appropriate. Categorical variables are presented as abso-
lute and relative frequency. The comparisons of continu-
ous variables between subjects with different levels of 
impairment in functional status were performed with 
Kruskal–Wallis test, as the dependent variables were not 
normally distributed for each group of the PCFS Scale. 
The comparisons of categorical variables between sub-
jects with different level of impairment in functional 
status were performed with a Chi-square test of inde-
pendence or Mantel–Haenszel test of trend, as appropri-
ate. The tests were followed by Bonferroni adjustments 
for multiple comparisons. An ordinal logistic regres-
sion was performed to determine which of the baseline 
characteristics were associated with a higher odd of being 
in a higher grade of the PCFS Scale. Statistics and visu-
alization were performed using SPSS (version 25, IBM 
Corporation, Armonk, NY, USA) and GraphPad Prism 
9.0 (GraphPad Software Inc., USA). A priori, the level of 
significance was set at P < 0.05.
Results
General characteristics
From the initial 2159 respondents, 15 were excluded 
because of ICU admission during the infection, 22 were 
excluded because of reported onset of symptoms before 
January 1, 2020 or within the previous 21 days, and 183 
were excluded due to incomplete surveys. Therefore, a 
total of 1939 subjects (85% women, 46 ± 11  years, body 
mass index (BMI): 25.2[22.6–28.8]kg/m2) were included 
in the analyses. The general characteristics of these sub-
jects are presented in Table  1. The time from onset of 
symptoms to the day of the participation in the study was 
on average 79 ± 17 days. The majority of the subjects was 
diagnosed based on symptoms (42%), whereas 17% were 
diagnosed based on CT/RT-PCR and 36% had no formal 
COVID-19 diagnosis. Five percent of the subjects were 
hospitalized with confirmed COVID-19. In addition, 
the majority of subjects were married or living together 
(71%), reported no previous comorbidities (61%), and 
had no previous smoking habits (82%). Most of the sub-
jects reported moderate-to-slight functional limitations 
according to the PCFS Scale (85%) while only 3% of the 
subjects reported to currently have no limitations in daily 
life.
Stratification for the grade on the PCFS Scale
The gender distribution, type of COVID-19 diagnosis, 
presence of self-reported pre-existing comorbidities and 
marital status were different among the PCFS Scale cat-
egories. Interestingly, no differences in the proportion 
of smoking status were presented (Table  1). Additional 
file 1: Fig. 1 displays the odds of being in a higher grade of 
the PCFS Scale according to gender, BMI category, type 
of COVID-19 diagnosis, marital status, presence of self-
reported pre-existing comorbidities and smoking status. 
Additional file 1: Table 1 displays the prevalence of each 
specific pre-existing comorbidities according to the dif-
ferent groups of the PCFS Scale grades.
Subjects with no functional limitations were older 
compared to subjects presenting slight, moderate and 
severe functional limitations. Subjects with severe func-
tional limitations (Grade 4 on the PCFS Scale) presented 
lower BMI compared to all other groups (Table 1). Nota-
bly, other factors associated with poorer functional status 
were marital status (prevalence of category ‘alone’ high-
est in Grade 4) and presence of comorbidities (prevalence 
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of ‘≥ 2 comorbidities’ highest in Grade 4). Interestingly, 
subjects with severe functional limitations also had the 
highest prevalence of a ‘symptom-based’ COVID-19 
diagnosis.
The most intense symptoms reported were fatigue, 
muscle weakness and sleeping problems while the least 
were fever, nausea and dysphagia. Subjects classified as 
experiencing slight, moderate and severe functional limi-
tations presented a gradual increase in the number and 
intensity of symptoms (Table 1 and Fig. 1). No differences 
were found between subjects with negligible functional 
limitations and no functional limitations concerning the 
number and intensity of symptoms (Fig. 1).
HrQoL was comparable between subjects with neg-
ligible functional limitations and no functional limita-
tions, while all other pairwise comparisons including 
the subjects with slight, moderate and severe functional 
limitations showed worsening of HrQoL for increas-
ing categories of the PCFS Scale (Fig.  2a). We found 
weak-to-strong associations between functional sta-
tus and all domains of HrQoL (r: 0.233–0.661; P < 0.01) 
(Fig.  2b). Notably, the strongest association found was 
Table 1 Baseline characteristics of  the  subjects with  COVID-19 stratified according to  the  level of  impairment 
in functional status
COVID-19 corona virus disease 2019, BMI body mass index
a P < 0.05 compared with Grade 0; bP < 0.05 compared with Grade 1; cP < 0.05 compared with Grade 2; dP < 0.05 compared with Grade 3
Variables Total sample Post-COVID-19 Functional Status Scale
Grade = 0 Grade = 1 Grade = 2 Grade = 3 Grade = 4
(n = 1939) (n = 58, 3%) (n = 157, 8%) (n = 643, 33%) (n = 1011, 52%) (n = 70, 4%)
General
Women, n (%) 1652 (85) 46 (79) 118 (75) 538 (84) 890 (88)b 60 (86)
Age (years) 46 ± 11 51 ± 12 47 ± 11 46 ± 11a 46 ± 10a 45 ± 12a
BMI (kg/m2) 25.2 [22.6–28.8] 26.1 [24.3–29.1] 25.6 [23.1–28.3] 25.2 [22.7–28.7] 25.2 [22.5–29.3] 22.5 [20.5–26.7]a,b,c,d
Underweight (BMI < 18.5), n (%) 27 (1) 0 (0) 2 (1) 4 (0.6) 18 (2) 3 (4)c
Normal weight (BMI: 18.5–24.9), n (%) 901 (47) 21 (36) 67 (43) 301 (47) 468 (46) 44 (63)a,b
Overweight (BMI: 25.0–29.9), n (%) 621 (32) 25 (43) 66 (42) 209 (33) 307 (31)b 14 (20)a,b
Obesity (BMI ≥ 30), n (%) 389 (20) 12 (21) 22 (14) 128 (20) 218 (22) 9 (13)
Time since first symptoms (days) 79 ± 17 77 ± 21 82 ± 19 79 ± 17 79 ± 16 83 ± 15
Number of reported symptoms, (n) 11 ± 3 7 ± 4 9 ± 4 10 ± 3a,b 11 ± 3a,b,c 12 ± 3a,b,c,d
COVID-19 Diagnosis
Hospitalized, test-based diagnosis, n (%) 102 (5) 9 (15) 6 (4)a 31 (5)a 52 (5)a 4 (6)
Non-hospitalized, test-based diagnosis, 
n (%)
319 (17) 17 (29) 30 (19) 120 (19) 144 (14)a 8 (11)
Non-hospitalized, symptom-based 
diagnosis, n (%)
820 (42) 14 (24) 43 (27) 253 (39) 473 (47)a,b,c 37 (53)a,b,c
Non-hospitalized, no formal diagnosis, 
n (%)
698 (36) 18 (31) 78 (50) 239 (37)b 342 (34)b 21 (30)
Self-reported pre-existing comorbidities
None, n (%) 1182 (61) 38 (65) 98 (62) 406 (63) 609 (60) 31 (44)c
1 comorbidity, n (%) 499 (26) 15 (26) 47 (30) 161 (25) 259 (26) 17 (24)
≥ 2 comorbidities, n (%) 258 (13) 5 (9) 12 (8) 76 (12) 143 (14) 22 (31)a,b,c,d
Marital Status
Alone, n (%) 404 (21) 14 (24) 26 (17) 126 (20) 211 (21) 27 (39)b,c,d
Married/Living Together, n (%) 1381 (71) 42 (72) 120 (76) 469 (73) 712 (70) 38 (54)b,c,d
Divorced, n (%) 130 (7) 2 (3) 8 (5) 41 (6) 74 (7) 5 (7)
Widow(er), n (%) 24 (1) 0 (0) 3 (2) 7 (1) 14 (1) 0 (0)
Smoking Status
Current smoker, n (%) 119 (6) 3 (5) 4 (2) 39 (6) 68 (7) 5 (7)
Stopped smoking after COVID-19, %, 
n (%)
226 (12) 8 (14) 23 (15) 78 (12) 108 (11) 9 (13)
Never smoked, n (%) 1594 (82) 47 (81) 130 (83) 526 (82) 835 (83) 56 (80)
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with the ‘usual activities’ domain of the 5-level EQ-5D 
questionnaire.
Figure  3 displays the comparison of the level of 
impairment in work and usual activities as assessed by 
the WPAI questionnaire. Absenteeism, presenteeism 
and work impairment were different considering all 
pairwise comparisons with exception of the compari-
son between subjects with no and negligible func-
tional limitations and between subjects with moderate 
and severe functional limitations. Activity impairment 
Fig. 1 Comparisons of symptoms intensity between subjects with COVID-19 stratified according to the level of impairment in functional status. 
Figure displays the median as central line, interquartile range as the limits of the box and 10 and 90 percentiles as whiskers. a P < 0.05 compared 
with Grade 0; b P < 0.05 compared with Grade 1; c P < 0.05 compared with Grade 2; d P < 0.05 compared with Grade 3 
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increased gradually according to the decrease in func-
tional status.
Discussion
This is the first study to describe the PCFS Scale in a 
large sample of adult hospitalized and non-hospitalized 
subjects with confirmed and presumed COVID-19. The 
present results confirm the hypothesis that the PCFS 
Scale can be used to measure the impact of symptoms 
on the functional status of subjects after COVID-19, 
especially in slight to severe categories. We found grad-
ual differences in the number and intensity of symp-
toms, reduction in HrQoL and impairment in work and 
usual activities between subjects with slight, moder-
ate and severe functional limitation status (≥ grade 2) 
while no differences between subjects with no func-
tional limitation (grade 0) and negligible functional 
limitation (grade 1) were found when comparing these 
outcomes, although a lack of power to detect small but 
Fig. 2 A Comparisons of HrQoL of life between subjects with COVID-19 stratified according to the level of impairment in functional status. a 
P < 0.05 compared with Grade 0; b P < 0.05 compared with Grade 1; c P < 0.05 compared with Grade 2; d P < 0.05 compared with Grade 3. Figure displays 
the median as central line, interquartile range as the limits of the box and 10 and 90 percentiles as whiskers. B Associations between level of 
impairment in functional status and different domains of HrQoL
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meaningful differences among the latter groups might 
have affected these results.
The majority of the included subjects was not formally 
tested during the infection (78%), whereas a minority 
was hospitalized with confirmed diagnosis of COVID-19 
(5%). These findings are expected, as early data showed 
that the proportion of critical cases of COVID-19 is 5% 
[2] and the number of undocumented infections have 
been estimated at 86% of all infections [3]. When propos-
ing the PCFS Scale, Klok and colleagues underlines the 
relevance of the assessment of functional status in the 
weeks and months following acute care of COVID-19 
subjects [8]. Our findings describe that, despite the inclu-
sion of a middle aged sample of subjects without multi-
ple comorbidities and with diagnosis of ‘mild’ COVID-19 
(i.e. non-hospitalized during the infection), the major-
ity of them (85%) report slight-to-moderate functional 
limitations during course of COVID-19, 3  months after 
the onset of symptoms, supporting the existence of a 
‘post-COVID-19 syndrome’ [14] which may be a target 
for deciding on referral of non-hospitalized subjects to 
expert (outpatient) clinics, facilitate selection of subjects 
who may benefit from rehabilitation programs as well as 
measuring the efficacy of such programs.
Of note, one of the strong points of the scale is that 
it intentionally does not specify why subjects are func-
tionally impaired, i.e. if the impairment is caused by 
dyspnoea, fatigue, pain, anxiety or otherwise. This is 
crucial for the scale to be useful in a condition that 
may cause symptoms in many organ systems. However, 
Fig. 3 Comparisons of work productivity and activity impairment between subjects with COVID-19 stratified according to the level of impairment 
in functional status. a P < 0.05 compared with Grade 0; b  P < 0.05 compared with Grade 1; c P < 0.05 compared with Grade 2; d  P < 0.05 compared with 
Grade 3. Figure displays the median as central line, interquartile range as the limits of the box and 10 and 90 percentiles as whiskers
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it does not rule out the fact that the reported func-
tional limitations are (partly) pre-existent. This is no 
issue when the scale is measured repeatedly or used as 
outcome measure in studies comparing two or more 
groups, especially in randomized controlled trials. The 
manual to the scale describes the possibility to assess 
pre-COVID-19 functional status, which would allow 
for determination of the causality of functional impair-
ment in observational studies [10]. Importantly, since 
the aim of the current study was to assess the associa-
tions between measures of symptoms intensity, HrQoL, 
impairment in work and usual activities due to health 
and the PCFS Scale, these considerations do not pose 
an issue for the correct interpretation of the presented 
data, nor does the fact that COVID-19 was not con-
firmed by objective testing in all subjects.
As most of the included subjects in our study were 
highly symptomatic and the PCFS Scale has shown to 
be associated with number and intensity of symptoms, 
the groups of subjects stratified as presenting no func-
tional limitations (grade 0) and negligible functional 
limitations (grade 1) were relatively small (3% and 8% of 
total sample, respectively) likely due to a selection bias 
arising from the self-selection nature of the data. Also, 
the lack of statistically significant differences between 
these groups could be a direct consequence of this lim-
ited number of subjects. It is also possible that there is, 
in fact, not a clinically relevant difference in outcomes 
between these two grades of the PCFS Scale, future 
studies with inclusion of less symptomatic subjects are 
necessary to investigate this issue. After all, both a scale 
grade of 0 and 1 indicate no functional limitations. The 
clinical relevance between the 2 grades is possibly to 
differentiate full recovery (grade 0) from incomplete 
recovery and persistent symptoms (grade 1).
The groups of subjects stratified as presenting slight 
and moderate functional limitations (grade 2 and 3) 
present similar baseline characteristics, however with 
a gradual increase in number/intensity of symptoms, 
reduction in HrQoL and impairment in work and 
usual activities. Despite presenting significantly lower 
BMI, the relatively small group of subjects with severe 
functional limitations (grade 4) was found to be highly 
symptomatic and presenting worse HrQoL. This could 
be partially explained by the higher proportion of sub-
jects with multimorbidity included in this group, since 
previous studies have found that multimorbidity is an 
independent factor associated with HrQoL [24, 25]. 
Furthermore, this group of subjects also presented a 
higher proportion of subjects with other factors that 
are associated with poorer functional status such as liv-
ing alone and presenting a ‘symptom-based’ COVID-19 
diagnosis.
The main limitation of the present study is the inclu-
sion of a self-selected sample of subjects with confirmed 
and presumed COVID-19 who are still symptomatic after 
the infection, it is possible that the frequency and inten-
sity of symptoms reported by non-hospitalized subjects is 
overestimated due to selection bias and due to the inclu-
sion of a relatively high proportion of women, who usu-
ally report more symptoms than men [26]. Moreover, if 
COVID-19 ICU survivors and other hospitalized subjects 
would have been included, the distribution of the PCFS 
could have shifted towards more symptoms and func-
tional impairment. Future studies should investigate the 
distribution of the scale grades in less selected cohorts 
of COVID-19 subjects, as well as confirm the identified 
associations in other samples including a higher propor-
tion of men, less symptomatic subjects and in sequential 
assessment of the scale during the course of disease (e.g. 
at the time of hospital discharge, more than 3  months 
after the onset of symptoms). In addition, we did not 
include any objective measure of physical function-
ing that could be related to functional status, however 
the strong association with the domain ‘usual activities’ 
of the EQ-5D-5L and WPAI and the ability to discrimi-
nate subjects with higher number/intensity of symptoms 
demonstrate the construct validity of the PCFS Scale.
Conclusion
In conclusion, we demonstrated the construct validity 
of the PCFS Scale in highly-symptomatic adult subjects 
with confirmed or presumed COVID-19 3 months after 
the onset of symptoms. The fact that the PCFS Scale can 
be easily used is a major advantage of the scale, poten-
tially facilitating its widespread implementation. We pro-
pose that this tool could be used to discriminate between 
subjects with higher number and intensity of symptoms 
which is related with reduced HrQoL and impairment 
in work and usual activities. Therefore, the scale could 
be used to guide follow-up procedures such as referral 
to expert (outpatient) clinics or rehabilitation programs. 
Also, this shows that the PCFS Scale could be consid-
ered as a main outcome in clinical trials as well as obser-
vational studies, as it captures symptom intensity and 
HrQoL in one meaningful scale. The construct validity is 
a first step towards the validation of the PCFS Scale and 
more studies assessing other measurement properties are 
recommended.
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